Nebenwirkungen · Remicade
Remicade 100 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 16–17
HOS-089890 · Präparat HOS-083941
16 * including bovine tuberculosis (disseminated BCG infection), see section 4.4 1 At month 12 of the controlled period for adult clinical trials across all indications, the median weight increase was 3.50 kg for infliximab-treated subjects vs. 3.00 kg for placebo-treated subjects. The median weight increase for inflammatory bowel disease indications was 4.14 kg for infliximab-treated subjects vs. 3.00 kg for placebo-treated subjects, and the median weight increase for rheumatology indications was 3.40 kg for infliximab-treated subjects vs. 3.00 kg for placebo-treated subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-15T13:59:00Z · SHA-256 3fe5ec643ebd8b47f3d2adf8a19ade1224c614e70c07c2d563b0cf68054693ab · Passage 891eb984dda68ca4306f34a106c8b3be99e34e653f9103a98b748be6f5404b62 · Zeichen 9431–10036 im Abschnitt